PD2-3 Towards Optimal Management of Metastatic Renal Cell Carcinoma : an Update on the Role of Sunitinib as First-line Treatment
Year: 2008
Type: article
Abstract: Sorafenib.a multikinase inhibitor, inhibits both tyrosine (such as VEGFR and PDGFRb) and serinelthreonine-specific kinases (such as c-RaD.Two phaseIstudies established a suggest phase II dose of 4eOmg twice daily oraly on a continu- eus basis, although another suggested that higher doses were possible.Subsequently a randomized
Source: The Japanese Journal of Urology
Author: Brian I. Rini
Institution: Cleveland Clinic
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W393870016